Recent

% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

shoenfield 592 posts  |  Last Activity: 5 hours ago Member since: Jan 1, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • shoenfield shoenfield 5 hours ago Flag

    And down in AH's

  • Reply to

    I Am Buying Thank You

    by wcamp32000 May 4, 2016 11:37 AM
    shoenfield shoenfield 5 hours ago Flag

    Check the cancer rate.

  • Reply to

    I Am Buying Thank You

    by wcamp32000 May 4, 2016 11:37 AM
    shoenfield shoenfield 5 hours ago Flag

    Really. Thanks for telling us.

  • Gogo partnering on installs with European air group

    May 5 2016, 16:00 ET | By: Jason Aycock, SA News Editor

    Gogo (GOGO +1.5%) is partnering with International Airlines Group in order to bring its 2Ku in-flight technology to dozens more aircraft.

    It's the first European airline group to commit to Gogo's next-gen solution.

    The company will deploy 2Ku on 118 aircraft at British Airways, four Boeing 757s at Aer Lingus (OTC:AIRXY) and up to 15 long-haul craft at Iberia.

    Most installations are set to be completed by 2019; the first British Airways craft is set for service early next year.

  • shoenfield by shoenfield 7 hours ago Flag

    Geron Corporation Reports First Quarter 2016 Financial Results and Recent Events
    Thu May 5, 2016 4:05 PM|GlobeNewswire | About: GERN


    GlobeNewswire
    MENLO PARK, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (GERN) today reported financial results for the first quarter ended March 31, 2016 and recent events.

    First Quarter 2016 Results

    For the first quarter of 2016, the company reported operating revenues of $749,000 and operating expenses of $9.8 million compared to $537,000 and $10.0 million, respectively, for the comparable 2015 period. Revenues for the first quarter of 2016 and 2015 included royalty and license fee revenues under various non-imetelstat agreements. Operating expenses in the first quarter of 2015 included restructuring charges of $406,000 in connection with the company’s organizational resizing announced in March 2015. Net loss for the first quarter of 2016 was $8.8 million, or $0.06 per share, compared to $9.3 million, or $0.06 per share, for the comparable 2015 period. The company ended the first quarter of 2016 with $141.9 million in cash and investments.

    Research and development expenses for the first quarter of 2016 and 2015 were $5.0 million for each period. Research and development expenses for 2016 primarily reflect the net result of higher costs for the company’s proportionate share of clinical development expenses under the imetelstat collaboration with Janssen Biotech, Inc. (Janssen), partially offset by lower personnel related expenses as a result of the 2015 organizational resizing. The company expects research and development expenses to increase during the remainder of the year as the clinical development of imetelstat continues in collaboration with Janssen.

    General and administrative expenses for the first quarter of 2016 were $4.8 million compared to $4.6 million for the comparable 2015 period. The increase in general and administrative expenses primarily reflects the net result of higher non-c

  • Reply to

    No early morning volume!

    by hairypotter9 13 hours ago
    shoenfield shoenfield 13 hours ago Flag

    Earnings today.

  • Reply to

    CRITICAL MASS SELLOFF

    by dazetrader824 May 4, 2016 3:18 PM
    shoenfield shoenfield May 4, 2016 3:19 PM Flag

    Really, thanks so much for telling us that.

  • Reply to

    Sold

    by jwjmurphy Apr 6, 2016 10:24 PM
    shoenfield shoenfield May 4, 2016 3:16 PM Flag

    Good one, sage.

  • shoenfield shoenfield May 4, 2016 3:15 PM Flag

    You tell em to! Longs in till the fat lady sings!

  • shoenfield shoenfield May 4, 2016 3:14 PM Flag

    You tell em!

  • shoenfield shoenfield May 4, 2016 3:10 PM Flag

    Where's the bounce???????????????

  • shoenfield by shoenfield May 4, 2016 3:06 PM Flag

    Gogo (NASDAQ:GOGO) -- down as much as 6.5% today after it was brought up as a short idea at the Ira Sohn conference -- jumped in recent minutes back into positive ground on news that Delta Air Lines (NYSE:DAL) is adding Gogo's offering to at least 350 aircraft.

    That brings Delta's commitment to Gogo's 2Ku in-flight Wi-Fi tech to more than 600 mainline aircraft.

    The installation will offer Delta's customers bandwidth more than 20 times Gogo's ATG technology, Delta says, making for easier video streaming.

    Now read Gogo And Airbus Strike A Deal »

  • Zacks
    By Arpita Dutt
    May 3, 2016 9:20 AM

    Geron Corporation GERN is scheduled to report first quarter 2016 results on May 5 after the market closes. The company’s fourth quarter 2015 loss was in-line with expectations. Let’s see how things are shaping up for the first quarter announcement.

    Focus Remains on Imetelstat

    With Geron being a development stage company, investor focus will remain on the company’s pipeline progress. Geron currently has one candidate in its pipeline, imetelstat, which is being developed in collaboration with Johnson & Johnson’s JNJ Janssen Biotech.

    Imetelstat is currently in a phase II study (IMbark) in patients with DIPSS intermediate-2 or high-risk myelofibrosis who have relapsed after or are refractory to a JAK inhibitor. An internal review to determine the adequacy of one or both of the initial dosing arms is slated for the second half of the year. Based on this review, a decision will be taken regarding the continuation/halting/modification of the dosing arms or the selection of alternative doses.

    Imetelstat is in a phase II/III study as well for myelodysplastic syndrome (MDS). An internal review of this study (to support advancement into Part 2) is also expected in the second half of the year.

    On the fourth quarter call, Geron had guided towards cash operating expenses of approximately $34 million in 2016 – this includes $18 million representing Geron’s share of cost for the studies under the Janssen collaboration, about $9 million in personnel related cost, and $7 million for corporate costs like business development, legal, accounting, IT and facilities.

    In addition to updates on imetelstat, investors will also be interested to know if Geron has made any progress in expanding its pipeline. The company is seeking to add new oncology candidates, programs or companies to its portfolio with its focus primarily on the hematology-oncology space.

    Surprise History

    Geron’s performan

  • Reply to

    boy it looks bad! Was I wrong?

    by ptcamd May 3, 2016 10:43 PM
    shoenfield shoenfield May 4, 2016 1:51 PM Flag

    Really. What about the longs who have held for a decade, got any pearls of wisdom for them? Really.

  • Reply to

    Buy now and double up before year end.

    by woofs_a_lot May 4, 2016 1:10 PM
    shoenfield shoenfield May 4, 2016 1:48 PM Flag

    Really. Thanks for the valuable post.

  • Reply to

    Folks

    by shoenfield May 4, 2016 11:32 AM
    shoenfield shoenfield May 4, 2016 1:45 PM Flag

    Try to stay on point, Gern,

  • shoenfield by shoenfield May 4, 2016 11:32 AM Flag

    Gern on sale continues. The elevator is going down. Many are predicting a USA recession by end of year.
    Will take great news to buck the overall trend and most likely this "new" is not coming for 12 to 24 months. What say you?

  • Reply to

    FYI

    by shoenfield May 3, 2016 4:01 PM
    shoenfield shoenfield May 3, 2016 4:58 PM Flag

    Maineman, ...due to a recent financial set-back? How about a 15 year financial set back from Gern?
    No need for an SOS I'm told help is coming, 6 to 18 months out, should I believe it old wise one?

  • Reply to

    FYI

    by shoenfield May 3, 2016 4:01 PM
    shoenfield shoenfield May 3, 2016 4:52 PM Flag

    Really. Good for you.

  • shoenfield by shoenfield May 3, 2016 4:01 PM Flag

    The pumpers will tell you it's on sale today (again). Obviously the tide went out today and it took all boats.

MNKD
1.35-0.06(-4.26%)May 5 4:00 PMEDT